Mounting evidence suggests that vitamin D has anticancer properties beyond its established roles in bone health. Low vitamin D status is associated with higher risks of colon, breast, prostate, and pancreatic cancers in epidemiologic studies (1-5). Recent estimates indicate that 1 billion people worldwide are vitamin D deficient or insufficient (6) . Moreover, serum vitamin D levels have been declining in the US population over the past decades (7) . The main source of vitamin D is exposure to sunlight (ultraviolet B Although the kidney is the primary organ for vitamin D metabolism, the association between vitamin D and renal cell cancer (RCC), the most prevalent form of kidney cancer, is unclear. RCC incidence is increasing worldwide, but the rates vary widely across populations. Eastern and northern Europe, the United States, and Canada have 10 to 15 times higher RCC prevalence than Asia and Africa (9) . In the United States, blacks have higher RCC incidence than whites (10) (11) (12) . The increasing trends in RCC and the geographic and racial disparities are still largely unexplained (10) .
One plausible explanation might be low vitamin D status. Vitamin D deficiency is highly prevalent among blacks (3, 7) . Several ecologic studies have suggested an inverse relationship between solar UV-B irradiance and RCC incidence or mortality (13, 14) . Conversely, a recent pooled nested case-control study reported no association between a prediagnostic circulating 25(OH)D level and RCC risk (15) . Although the study had an advantage of using a direct blood measure, a single baseline measurement might not adequately represent long-term average vitamin D status over years or decades (16) .
In large-scale epidemiological studies, measuring blood 25(OH) D in a whole population multiple times for a long-term period might not be feasible (17) . Therefore, we developed predicted 25(OH)D scores that take into account the combined influences of major determinants of circulating 25(OH)D (17, 18) . The score can be used in a wider range of population without blood samples and also be updated multiple times during follow-up. In this study, we prospectively investigated the association between predicted plasma 25(OH)D score and RCC risk in two independent cohorts of men and women in the United States. We also examined the relationship between vitamin D intake and RCC incidence.
Methods

Study Population
The Nurses' Health Study (NHS) was established in 1976, when 121 700 US female registered nurses aged 30 to 55 years were enrolled. The Health Professionals Follow-Up Study (HPFS) began in 1986 and consisted of 51 529 US male health professionals aged 40 to 75 years. For both cohorts, baseline and follow-up questionnaires were sent every 2 years to update information on lifestyle factors and diagnosed diseases. These cohorts are described in detail elsewhere [(19,20) and Supplementary Methods, available online].
Derivation of Predicted Plasma 25(OH)D Score
Compared with dietary vitamin D, plasma 25(OH)D is considered a better indicator of vitamin D status because it has a relatively long half-life (approximately 3 weeks), is unregulated by homeostatic systems in the body, and accounts for multiple determinants (eg, sun exposure, skin pigmentation, and dietary intake) (21, 22) .
Prediction models of plasma 25(OH)D in these cohorts have been described elsewhere (17, 18) . Briefly, we developed separate prediction models from samples of 2079 women (NHS) and 911 men (HPFS) who had available plasma 25(OH)D measurements and were free of diagnosed cancer at the time of blood draw. Mean plasma 25(OH)D levels were 29 (standard deviation [SD] = 11) ng/mL in female samples and 26 (SD = 10) ng/mL in male samples (17) . Using multivariable linear regression with the measured plasma 25(OH)D as the dependent variable, we derived predicted 25(OH)D scores based on the known determinants of vitamin D status: race (surrogate for skin pigmentation), UV-B radiation flux at residence, leisure-time physical activity (surrogate of outdoor exposure to UV-B), body mass index (BMI), dietary and supplemental vitamin D intakes (see below), alcohol intake, and postmenopausal hormone use (in women).
To validate these prediction models, we used independent samples of 779 women (NHS) and 836 men (HPFS) who had plasma 25(OH)D measurements. Based on data from a previously published case-control study in these cohorts (17) , the calculated odds ratios of colorectal cancer for both measured and predicted 25(OH)D were similar (0.82 and 0.78 per 10 ng/mL increment, respectively). These findings suggest that a predicted 25(OH)D score is an acceptable marker for ranking individuals by vitamin D status (17) .
In this analysis, we started follow-up in 1986, when leisure-time physical activity was first assessed, for the evaluation of vitamin D score and RCC risk in both cohorts. We excluded individuals who had missing information on the determinants of predicted 25(OH) D score at baseline.
Estimation of Vitamin D Intake
To assess dietary intake, self-administered semiquantitative foodfrequency questionnaires were sent every 2 to 4 years (Supplementary Methods, available online). Information on current use and dose of multivitamins and supplements was also collected biennially. Total vitamin D intake included intakes from both diet and supplements (vitamin D-specific supplements or multivitamins containing vitamin D).
For the evaluation of vitamin D intake and RCC risk, we started follow-up in 1980 in the NHS and 1986 in the HPFS. We excluded individuals who had missing data on vitamin D intake at baseline.
Ascertainment of Renal Cell Cancer and Other Covariables
The primary endpoint of this study was newly diagnosed RCC. Self-reported information on incident kidney cancer was obtained in each biennial questionnaire. Participants (or next of kin on behalf of decedents) who reported the cancer diagnosis were asked for permission to access medical and pathological records. Physicians blinded to participants' information reviewed the records. Based on the World Health Organization classification (23), we included as RCC cases the following subtypes: clear cell, papillary, chromophobe, collecting duct carcinoma, and RCC not otherwise classified. We excluded individuals who reported any cancer (except for nonmelanoma skin cancer) at baseline and kidney cancer not confirmed by pathological reports. Assessment of covariables is described in the Supplementary Methods (available online).
Statistical Analysis
We calculated person-years of follow-up from the date of return of the baseline questionnaire to the date of RCC diagnosis, death from any cause, or the end of follow-up (June 2008 for the NHS and January 2008 for the HPFS), whichever came first.
To better represent long-term vitamin D status and reduce measurement error, we used cumulative averages of predicted 25(OH)D scores and vitamin D intake derived throughout the entire follow-up period (from baseline to the time of censoring events) (24)-for examples, see the Supplementary Methods (available online). We used energy-adjusted vitamin D intake calculated by the regression-residual method to remove the variation due to energy intake and its correlated measurement error (25) . Predicted 25(OH)D score and vitamin D intake were categorized into quintiles in each cohort with the lowest quintiles as references. We also used predicted 25(OH)D score as a continuous variable and analyzed for an increment of 10 ng/mL, which approximately corresponded to the plasma level differences between the extreme deciles of predicted score in the validation studies (18) .
Cox proportional hazards regression models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) (Supplementary Methods, available online). The proportional hazards assumption was verified by modeling interaction terms between age and the main exposures. In multivariable analyses of predicted 25(OH)D score, we adjusted for potential confounders: age, smoking (never, past, current), history of hypertension or diabetes, and parity (in women; nulliparous, 1-2, 3, 4, ≥5 children). We did not include BMI in the primary model because BMI is an important determinant of predicted 25(OH)D score (thus, controlling for BMI may be considered an overadjustment) (17) and also might be in the causal pathway (26) . In the secondary analysis, we further adjusted for BMI to examine an independent role of 25(OH)D on RCC development. In multivariable analyses for vitamin D intake, we adjusted for all of the covariables used for predicted 25(OH)D as well as total caloric intake (quintile). Dietary and supplemental vitamin D intakes were mutually adjusted for each other.
Tests for trend were conducted by assigning the median value to each category of vitamin D and modeling this value as a continuous variable. We performed subgroup analyses to examine whether the association between predicted 25(OH)D score and RCC varied across strata of established RCC risk factors: age (<65, ≥65 years), BMI (<27.5, ≥27.5 kg/m 2 ), smoking (ever, never), and history of hypertension (yes, no). Tests for interaction were performed by the Wald test, using cross-product terms of 25(OH)D score and stratification variables.
In sensitivity analyses, we examined latency periods between predicted 25(OH)D score and RCC, which has relatively slow proliferation and unknown latency. Because we obtained repeated computations of predicted 25(OH)D every 2 years, we performed various latency analyses: 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 10, and 10 to 12 years. We also calculated measurement error-corrected hazard ratios using the risk set regression calibration method (27) .
We conducted separate analyses for each cohort and then pooled the hazard ratios from two cohorts with meta-analytic methods using a random effects model (28) . All P values were twosided, and P less than .05 was considered statistically significant. Statistical tests were performed using SAS software, version 9.3 (SAS Institute, Cary, NC). (Table 2 ). After adjustment for age, smoking, history of hypertension or diabetes, and parity (in women), the multivariable hazard ratios for top vs bottom quintiles were 0.50 (95% CI = 0.32 to 0.80; P trend < .001) in women and 0.59 (95% CI = 0.37 to 0.94; P trend = .04) in men; the pooled hazard ratio was 0.54 (95% CI = 0.39 to 0.75; P trend < .001). Further adjustment for BMI somewhat attenuated the associations, but the inverse trends remained statistically significant. When we used the continuous form of the predicted 25(OH)D score, similar inverse associations were observed. An increment of 10 ng/mL in predicted 25(OH)D was associated with a 43% (HR = 0.57, 95% CI = 0.40 to 0.80) lower incidence of RCC in women, a 46% (HR = 0.54, 95% CI = 0.34 to 0.87) lower incidence in men, and a 44% (HR = 0.56, 95% CI = 0.42 (29), we considered the possibility that hypertension might be in the causal pathway between vitamin D and RCC. When hypertension was removed from model 2, the hazard ratio did not change materially (per 10 ng/mL increment in predicted 25(OH)D: pooled HR = 0.64, 95% CI = 0.46 to 0.90). Similar results were observed when we removed diabetes from the model (data not shown).
In sensitivity analyses using 0-to-2-year to 10-to-12-year lags, the pooled multivariable hazard ratios (model 2) per 10 ng/mL increment in predicted 25(OH)D score ranged from 0.69 to 0.78, all of which were similar to but less strong than the hazard ratio in the primary model using cumulatively averaged predicted scores.
In stratified analyses, the inverse associations between predicted 25(OH)D score and RCC risk were consistent across strata of age, BMI, smoking, and history of hypertension (P interaction ≥ .454) (Figure 1 ).
Vitamin D Intake and the Risk of RCC
During 28 years of follow-up of 88 720 women and 22 years of follow-up of 47 886 men, we documented 263 RCC cases in women and 211 cases in men. We observed no statistically significant associations between estimated vitamin D intake and RCC risk (Table 3) . However, the highest quintile of total vitamin D intake compared with the lowest quintile showed a suggestive inverse relationship with RCC incidence (HR = 0.81, 95% CI = 0.60 to 1.09). Further adjustment for race, geographic region, physical activity, and alcohol, fruit, and vegetable intakes did not alter the results appreciably (data not shown).
Discussion
In these two independent cohorts, a higher predicted plasma 25(OH)D score was associated with a lower risk of RCC in both men and women. An increment of 10 ng/mL in predicted plasma 25(OH)D was associated with a 44% lower incidence of RCC. We found no statistically significant associations between estimated vitamin D intake and RCC incidence.
Previous epidemiologic studies yielded inconclusive results on the relationship between vitamin D and RCC risk. A hospitalbased case-control study reported statistically significantly lower serum vitamin D levels in RCC patients than in control subjects (30) , but sampling prevalent cases is not ideal because 25(OH)D levels may affect RCC prognosis and also the presence of the cancer may affect 25(OH)D levels. In a pooled, nested, case-control study of eight cohorts, a prediagnostic plasma 25(OH)D measurement was not associated with RCC risk; among subgroups, only women with the highest plasma 25(OH)D level (≥30 ng/mL; n = 14) had a statistically significantly lower risk (odds ratio = 0.31, 95% CI = 0.12 to 0.85) than those with the level of 20 to 29 ng/ mL (15) . However, the mean 25(OH)D level in participants of that study (18 ng/mL) was relatively lower than the levels in our samples of the NHS and HPFS (26-29 ng/mL) (17) . The intervals between blood collection and RCC diagnoses (median = 5.5 years) may not have adequately captured the etiologically relevant time period and varied across participating cohorts (interquartile range = 2.7-9.9 years). Furthermore, although they had the advantage of using a direct measure of circulating 25(OH)D, a single baseline measurement might not adequately represent long-term vitamin D status because it is substantially influenced by recent and acute exposures (eg, beach vacation or season) (17, 18) .
Some studies have focused only on vitamin D intake. An Italian case-control study (31) and prospective studies from Finland (32) and the United States (33) found no associations between vitamin D intake and RCC risk. These null associations might be because vitamin D intake is a relatively small contributor to circulating 25(OH)D levels. In the samples of the NHS and HPFS, only 3 ng/mL differences in measured plasma 25(OH)D were observed between extreme categories of dietary vitamin D intake (<100 vs ≥400 IU/day) (17) . Thus, combined influences of major components of predicted 25(OH)D score, such as physical activity, BMI, and UV-B exposure, might be more relevant in explaining the beneficial effects of vitamin D. Another explanation might be insufficient vitamin D intake in study populations. From a feeding study, at least 1500 IU/day of vitamin D supplementation was required to achieve a 10 ng/mL increment in plasma 25(OH)D (34). In our cohorts, vitamin D intake was generally less than 1000 IU/day, and participants in the highest quintile of total vitamin D intake had a marginally lower risk of RCC. Therefore, a higher amount of vitamin D intake might be required to reduce RCC risk.
Several plausible biological links might support the inverse association between vitamin D and RCC risk in our study. First, vitamin D has direct inhibitory effects on cancer development and progression at the cellular level (3, 35) . In in vitro and in vivo studies of human and murine RCC, vitamin D inhibited tumor cell proliferation, angiogenesis, clonogenicity, and metastasis, induced cell differentiation, and prolonged survival (36) (37) (38) (39) . Second, vitamin D may modify several risk factors for RCC, including hypertension, diabetes, and possibly obesity. Evidence is accumulating that vitamin D may play roles in controlling blood pressure (29) , blood glucose levels, and insulin sensitivity (40) . But even when we took into account that hypertension, diabetes, or obesity might be in the causal pathway, the effects through these factors were modest. This indicates that vitamin D has independent roles on RCC development.
Our study had several limitations. First, we used predicted 25(OH)D scores, which cannot be interpreted as direct blood measurements. Predicted 25(OH)D explained only a portion (ie, 28%-33%) of the total variability in plasma 25(OH)D levels (17) . However, predicted scores yielded similar results to measured plasma levels for the risks of colorectal, prostate, and pancreatic cancers and hypertension (5, 17, 18, 29) . Thus, predicted 25(OH)D may provide information comparable with measured plasma levels (17) , and multiple questionnaires may provide better information of long-term 25(OH)D status than a single blood measure. Second, the dose-response relationship between predicted 25(OH)D and RCC may not be applicable beyond the ranges of plasma 25(OH)D levels in our study participants. Third, our study population mainly consisted of white race, which may limit the generalizability of our results but reduces the possibility of confounding by race.
Our study had several strengths. This study had a prospective design with high follow-up rates. To our knowledge, this study provides the longest follow-up for the largest populations for investigating the relationship between vitamin D and RCC. We examined both predicted plasma 25(OH)D and vitamin D intake. To better approximate long-term vitamin D status, we updated the changes over time in vitamin D scores and intakes every 2 to 4 years. In the various latency analyses, the strongest association was found for the cumulative averages of 25(OH)D scores; presumably this means that long-term average levels of vitamin D are biologically most relevant to renal carcinogenesis. Our results for predicted 25(OH)D Figure 1 . Pooled multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) of renal cell cancer for a 10 ng/mL increment in predicted plasma 25-hydroxyvitamin D score across strata of various factors. Multivariable hazard ratios were adjusted for age (y), smoking status (never, past, current), history of hypertension, history of diabetes, body mass index (BMI; kg/m 2 , continuous), and parity (in women: 0, 1-2, 3, 4, ≥5 children) except for the stratified variable. The pooled hazard ratios were calculated by combining the multivariable hazard ratios from each cohort with meta-analytic methods using random effects model. All statistical tests were two-sided.
score were robust in both continuous and categorical analyses. We also updated information on most of the established RCC risk factors to reduce residual confounding. RCC cases were ascertained based on pathological evidence.
In conclusion, higher vitamin D status, averaged over the entire follow-up period of our studies, was associated with a statistically significantly lower risk of RCC in men and women. Further prospective studies using valid markers of long-term vitamin D status are warranted to confirm our results. * Cumulatively averaged vitamin D intake throughout the entire follow-up period (from baseline to the time of censoring events) was used. † Estimated by assigning the median value to each quintile and modeling this value as a continuous variable. ‡ Adjusted for age, body mass index (kg/m 2 , continuous), smoking status (never, past, current), history of hypertension, history of diabetes, intake of energy (quintile), and parity (in women: 0, 1-2, 3, 4, ≥5 children). Dietary vitamin D and supplemental vitamin D intakes were mutually adjusted for each other. § The multivariable-adjusted hazard ratios from each cohort were combined with meta-analytic methods using random effects model. All statistical tests were two-sided.
